We investigated the relationships between treatment characteristics and long-term outcomes in patients with locally advanced thymoma or thymic carcinoma.
T hymic malignancies, the most common primary neoplasms of the anterior mediastinum, are relatively rare and sometimes have an indolent course, making the choice of treatment and analysis of outcomes challenging. The few prospective trials that have included patients with advanced stage disease involved heterogenous treatments. 1 Retrospective and prospective analyses have demonstrated promising survival rates for patients undergoing multimodality therapy for advanced invasive thymoma [2] [3] [4] [5] or thymic carcinoma. [6] [7] [8] However, investigations that include large numbers of patients from several institutions are sparse, particularly those that compare patients who received different treatments.
We sought here to assess prognostic factors for survival for patients undergoing treatment for thymoma or thymic carcinoma, and to compare outcomes for patients who completed trimodality therapy with those for patients who received other less aggressive regimens. Specifically, our objectives were to: (1) report long-term outcomes in patients with locally advanced thymoma or thymic carcinoma treated at 2 major tertiary oncologic referral centers; (2) assess differences in survival outcomes between trimodality therapy versus less aggressive (single or bimodality) treatments; and (3) identify factors predictive of outcome for patients who underwent trimodality treatment. We hypothesized that patients with advanced thymic malignancies could achieve long-term survival with aggressive treatment and that patients with thymic carcinoma of any stage would have worse outcomes than patients with locally advanced invasive thymoma, even when accounting for treatment approach.
MATERIALS AND METHODS

Eligibility
The institutional review and privacy boards at each institution approved this study, and patient confidentiality was maintained as required by the Health Insurance Portability and Accountability Act. Institutional records were searched for patients receiving definitive treatment for Masaoka-Koga stages III to IVA thymoma or stages I to IVA thymic carcinoma at either The University of Texas MD Anderson Cancer Center or Memorial Sloan-Kettering Cancer Center from 1980 to 2011. Patients presenting with recurrent disease or distant metastasis (DM) were excluded, as were patients who were only partially or incompletely treated at these institutions.
Follow-up
Follow-up data were collected through September 3, 2012 from institutional records and records from referring facilities. Follow-up visits took place and images were obtained according to institutional standards, and those set forth by the National Comprehensive Cancer Network when available. 9 This generally consisted of a history and physical and repeat imaging (ie, CT scan of the chest) approximately every 6 months to 1 year for the first 5 years, with more frequent or extensive follow-up occurring at the physician's discretion. Patterns of failure were characterized in all patients who experienced disease recurrence; treatment failure within the bed of the thymus or intrathoracic recurrence not contiguous with the thymus (including the visceral and parietal pleura) was considered locoregional recurrence and all other sites of failure were considered DM. 10 Local failure in patients with an initial R2 or unresectable status was diagnosed based on clear progression radiographically and/or histologically after the completion of definitive therapy.
Statistical Analysis
Data analysis was done with Stata/MP 12.1 statistical software. The Fisher exact tests were used to assess measures of association in frequency tables. Survival probabilities were estimated using the Kaplan-Meier methods, and the log-rank tests were used to assess the equality of the survivor function across groups. The equality of group medians was assessed with the nonparametric tests for equality. A P-value of r0.05 was considered to be statistically significant. The statistical tests were based on a 2-sided significance level.
Survival times were calculated from the date of diagnosis to that of the first occurrence of the considered event (locoregional alone, DM alone, or any recurrence, locoregional or distant). Overall survival (OS) was defined as the time between diagnosis and death from any cause. Freedom from recurrence (FFR) was defined as the time between the date of diagnosis and the first evidence of recurrent disease (locoregional). These criteria are in accordance with the International Thymic Malignancy Interest Group's-recommended standard outcome measures for patients who have undergone curativeintent treatment. 10 The Cox proportional hazards model was used for multivariate analysis to assess the effect of the following variables on OS: age, sex, ethnicity, stage, histology, treatment, margin status, performance status, and diagnosis year. Estimated hazards were reported with 95% confidence intervals. All factors found to have a P-value of r0.25 on univariate analysis were included in the multivariable analysis, with each factor eliminated in a step-wise manner until the most significant variables were identified. The Wald test was used to assess the role of covariates in the model. Competing risks regression analysis was done according to the method of Fine and Gray, 11 with a similar selection of predictive factors for multivariable analysis. Subhazard ratios are reported for FFR with death as the competing event.
RESULTS
We identified 146 patients who met our criteria, 110 with stages III to IVA invasive thymoma and 36 with stages I to IVA thymic carcinoma. Patient characteristics are listed in Table 1 . The study population consisted of 82 (56%) men and 64 (44%) women, with a median age at diagnosis of 53 years (range, 13 to 89 y); 104 patients (71%) were white, and 64 patients (44%) had a baseline Eastern Cooperative Oncology Group (ECOG) performance score of 1. Eighteen patients (12%) were also diagnosed as having myasthenia gravis. Table 2 summarizes treatment characteristics for the study population. Eighty-seven patients (60%) received trimodality treatment (chemotherapy, surgery, and radiation therapy), 45 (31%) had bimodality treatment, and 14 (9%) underwent single modality treatment. Reasons for not undergoing trimodality treatment include: poor performance status (6%), progression of disease (1%), unresectable disease (20%), patient declined or lost to follow-up (6%), physician discretion (28%), or reasons not specified in the patient's records (39%). Of the 124 patients with surgically resectable disease, all underwent a thymectomy: 48 with an en bloc lung resection and 8 with extrapleural pneumonectomy. Fourteen patients had unresectable disease; all but 1 patient with unresectable disease received definitive radiation therapy, and all of these patients received chemotherapy. Thymectomy was performed most often through median sternotomy; other approaches included thoracotomy, hemiclamshell, clamshell, and video-assisted thoracotomy. Of those patients who underwent thymectomy, 60 had a complete resection. The median time to surgical resection after diagnosis was 3 months.
Treatment Characteristics
Of the 106 patients given chemotherapy, 60 received it as preoperative induction therapy, 20 as postoperative adjuvant therapy, and 26 as both preoperative and postoperative therapies. The most common regimen was cyclophosphamide, doxorubicin, and cisplatin (CAP), with or without prednisone (n = 64). Other combinations included cisplatin with etoposide (n = 9) and carboplatin with paclitaxel (n = 5). Of the 134 patients (92%) who received radiation therapy, 36 received 2-dimensional therapy, 30 received 3-dimensional conformal therapy, and 41 received intensity-modulated therapy, a pattern that reflected the technical advances in treatment planning and delivery over the period of study. Four patients underwent proton therapy, the first in 2009. The median radiation dose was 54 Gy (range, 54 to 66 Gy), delivered in 30 fractions (range, 10 to 50 fractions). The median interval between diagnosis and radiation therapy was 5 months.
Survival Outcomes According to Treatment Received
The median follow-up time was 63.8 months (range, 1.8 to 360.1 mo) for all patients and 64.1 months (range, 1.8 to 360.1 mo) for patients alive at the time of this analysis. OS and FFR at 5 and 10 years were as follows: OS, 80.7% and 58.3%; FFR, 81.4% and 64.6%. The 5-year OS and FFR for thymic carcinoma patients was 54.8% and 57.3%, respectively. Figure 1 shows Kaplan-Meier estimates of OS for those who received trimodality therapy (chemotherapy, surgery, and radiation) or nontrimodality therapy. When all cases were included in this comparison no significant difference was found (P = 0.2) ( Fig. 1A) . Of the patients with stage III disease who received surgery as part of their disease management, trimodality treatment showed better OS than those with nontrimodality treatment (Fig. 1B) .
Predictive Factors for Patients Who Underwent Trimodality Treatment
Patients who underwent chemotherapy, surgery, and radiation therapy were analyzed separately for the purposes of studying a more uniform patient population. Of this subgroup of patients who underwent trimodality treatment (n = 87), those with stage III disease showed better OS (P = 0.03) ( Fig. 2A ) and better FFR (P < 0.001) ( Fig. 2B ) than did patients with stage IVA disease. Table 3 describes the competing risk analysis for FFR with death (OS) as the competing risk. Univariate analysis showed that patients with stage IVA disease or a higher ECOG performance score (and thus worse performance status) had worse disease outcomes. No multivariable models for FFR were found to be significant.
Findings from the Cox regression analysis of OS for patients receiving trimodality treatment are shown in Table 4 . On univariate analysis, age older than 60 years, an ECOG performance status score of Z1, having R2 or unresectable disease, year of diagnosis, and having stage IV disease (with a trend toward significance) were linked with worse OS. On multivariate analysis for OS, having thymic carcinoma, R2 or unresectable disease, and an ECOG performance score of 1 to 3 were associated with worse OS. Note that neither age nor year of diagnosis was significantly associated with survival on multivariate analysis.
DISCUSSION
Here we present our findings from a large series of patients with locally advanced invasive thymoma or thymic carcinoma who had been treated at 2 tertiary cancer care centers with experience in treating these conditions. Our pertinent findings can be summarized as follows. First, although no difference in OS was found for all patients according to the aggressiveness of treatment received (trimodality vs. single or bimodality), patients with stage III disease obtained the greatest benefit from trimodality therapy, including improved OS. Second, factors identified as having predictive value for patients who underwent trimodality therapy included less advanced disease stage, a histologic diagnosis of thymoma, complete surgical resection, and better performance status (indicated by lower ECOG score). These factors identified are consistent with the findings of the International Thymic Malignancy Interest Group, which include completeness of resection, stage, and histology (specifically thymic carcinoma), but not sex or the presence of myasthenia gravis, as being predictive of survival. 12 Prior smaller studies of the role of trimodality therapy have concluded that this approach is promising for patients who can tolerate this aggressive form of therapy. For example, in a prospective analysis of 25 patients given trimodality therapy for advanced stage disease, Venuta et al 5 found that 8-year survival rates were 92% for those with stage III thymoma and 68% for those with limited stage IV disease. Another study of 16 patients with invasive thymoma (stage III and IVA) treated with trimodality therapy demonstrated a median survival time of 66 months and a 3-year survival rate of 70%. 13 Finally, in a smaller study of 7 patients with stage IIIA (Verley and Hollmann staging) invasive thymoma treated with neoadjuvant chemotherapy followed by surgery and postoperative radiation therapy, the reported 2-year survival rate was 80%. 14 Although retrospective, the current larger analysis of outcomes at 2 tertiary cancer care centers serves to validate these smaller studies and shows that long-term survival can be achieved with trimodality therapy when patients are selected appropriately. It should be noted, however, that although the greatest benefit in our study was shown in patients with stage III disease, in this retrospective and hypothesis-generating setting, we do not consider these results definitive. Indeed, aggressive treatment can be considered in patients with stage IVA disease if tolerable and at the treating physician's discretion. Further, our results show how adverse factors, such as histology or stage, affect the expected outcomes. These results will be useful for guiding the choice of treatment for patients with disease of specific subtypes to enhance the probability of long-term FFR and OS.
Trimodality therapy, with consolidative chemotherapy, could also be considered for patients with initially unresectable disease. One prospective study of 22 patients with locally advanced unresectable malignant thymoma showed that the use of induction chemotherapy to optimize the resectability of thymoma followed by radiation and consolidation chemotherapy led to improved control of residual disease and high OS rates. Indeed, 21 of the 22 patients in that study underwent surgical exploration after induction chemotherapy and 16 (76%) had complete resections. 15 Another reasonable approach is concurrent chemoradiation. In 1 trial of 26 patients with limited stage unresectable thymoma treated with CAP therapy and standard radiation to a total dose of 54 Gy, the overall response rate was 69.9% and the 5-year OS rate was 52.5%, results that compare favorably to those from single modality treatment. 16 At MD Anderson and Memorial Sloan-Kettering, the most commonly used regimen consists of upfront chemotherapy, with chemoradiation reserved for patients in whom surgery is considered less feasible.
Our results are also consistent with prior reports of poorer survival rates for patients with thymic carcinoma versus those with invasive thymoma. 17 In 1 large retrospective study of 1320 patients with thymic epithelial tumors in Japan, 18 the reported 5-year OS rate for patients with thymic carcinoma was 50.5%; however, clinical information on the patients in that study was somewhat limited. Consistent with our results, Huang et al 19 found differing patterns of relapse between patients with thymic carcinoma versus thymoma, with thymic carcinoma being associated with lower progression-free survival and higher rates of distant failures. If complete or incomplete resection can be achieved, long-term survival rates have been as high as 60% to 70% for those who receive adjuvant treatment. [6] [7] [8] A multimodality approach such as trimodality therapy or definitive concurrent chemoradiation in unresectable cases is recommended for thymic carcinoma regardless of disease stage. 20 In addition, only one third of patients with thymic carcinoma are able to undergo a complete resection. 17 More effective treatments for unresectable thymic carcinoma are thus needed, and several ongoing or recently completed clinical trials have assessed the effectiveness of adding targeted agents such as sunitinib. 21 Ideally, trials such as these will bring forth regimens that will improve outcomes for this difficult-to-treat disease.
In addition to the constraints of any retrospective study, our study had several limitations. First, given the rarity of the diagnosis of invasive thymoma or thymic carcinoma, our analysis included patients who had received a variety of treatments, including chemotherapy, radiation, and surgery. It may be difficult to differentiate between the effect of selection for a particular treatment and the effect of the treatment itself. We attempted to control for this limitation by analyzing patients in major subgroups to enhance the uniformity of the results and their applicability to other studies. We do acknowledge, however, that even though we controlled for performance status when comparing treatment regimens and identified reasons for not undergoing trimodality therapy, additional factors that cannot be reflected in this scoring system or documented in the medical record, such as a selection bias with regard to a patient's perceived ability to tolerate this procedure, may have confounded our outcomes. Regardless of this inevitable limitation, we attempted to control for pertinent clinical and disease variables in multivariate analysis, which strengthens our conclusion. Another limitation of our study lies in the long study period and hence wide range of treatment The bold numerals are those that have a P value less the 0.05. *The variables listed in the multivariate analysis are those that remained significant after backward stepwise elimination until the most parsimonious model was achieved.
CI indicates confidence interval; ECOG, Eastern Cooperative Oncology Group; HR, hazard ratio.
dates, another manifestation of the rarity of thymic malignancies. Nevertheless, although we do acknowledge the evolution of radiation and surgical techniques over time, we did find that the year of treatment did not adversely affect outcomes when other factors were taken into consideration in multivariate analysis, and thus this finding should not change the results and recommendations from this analysis.
CONCLUSIONS
Patients with advanced invasive thymic malignancies can achieve long-term survival after aggressive treatment that includes chemotherapy, surgical resection, and postoperative radiation therapy. Factors that are associated with the greatest benefit from this approach include low disease stage, a histologic diagnosis of thymoma versus thymic carcinoma, complete resection status, and good performance status. However, outcomes with this approach remain suboptimal in the setting of thymic carcinoma, despite treatment at 2 large tertiary cancer centers. Because of the high rate of DM, systemic imaging is essential in this subgroup, and the integration of systemic therapy is also of great importance. Studies examining novel agents in this scenario are needed.
